I. N. Kupriyanova

I. N. Kupriyanova

Auto-generated profile, based on publicly available information

I. N. Kupriyanova

Ural State Medical University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2024 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
LLL. B. Lazebnik
L. B. Lazebnik
STS. V. Turkina
S. V. Turkina
TET. V. Ermolova
T. V. Ermolova
Larisa V. TarasovaLarisa V. Tarasova
Larisa V. Tarasova
EPE. Yu. Plotnikova
E. Yu. Plotnikova
IKI. N. Kupriyanova
I. N. Kupriyanova
An increase in the amount of ammonia-ammonium in tissues plays a significant role in the development of human pathology. The appearance of an increasing number of publications emphasizes the urgency of the problem. A team of experts who took part in the XXVII Congress of the Scientific Society of Gastroenterologists of Russia (NOGR) on November 14, 2024 decided to make adjustments to the text of the Russian Consensus “Hyperammonemia in Adults” published in 2021 (Version 2021).

11 December 2021 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
IKI. N. Kupriyanova
I. N. Kupriyanova
VVV. A. Vedensky
V. A. Vedensky
EVE. Ya. Valieva
E. Ya. Valieva
MSM. A. Sinitsina
M. A. Sinitsina
Eradication therapy is the mainstay of treatment for H. pylori-associated diseases. A case of the development of tendinitis of the left patellar ligament proper during eradication therapy using a triple regimen with levofoloxacin for 14 days for exacerbation of duodenal ulcer is presented.

15 January 2024 in The Clinician
Verified
Journal Article
Open access
PDF file
SVS. S. Vedenskaya
S. S. Vedenskaya
OSO. G. Smolenskaya
O. G. Smolenskaya
VGV. G. Grachev
V. G. Grachev
EKE. S. Klyachina
E. S. Klyachina
IKI. N. Kupriyanova
I. N. Kupriyanova
VVV. A. Vedensky
V. A. Vedensky
Aim. To determine the features of hemostasis system disorders and the possibility of their correction in patients with arterial hypertension (AH) and multifocal atherosclerotic lesions (MFA) with risk factors indicated.Materials and methods. The study included 135 patients (mean age 53.7 ± 7.76 years), including 80 patients with controlled AH stage and II (group 1) and 55 patients with controlled AH stage III who had ischemic stroke (group 2). Among all patients studied, 33 patients (24.4 %) were smokers. All 135 patients received comparable antihypertensive, antiplatelettherapy (acetylsalicylic acid at a dose of 100 mg/day), had MFA and target lipid spectrum values.Results. Procoagulant shifts are noted already in patients with AH stage I and II, especially in the presence of smoking. Such indices of global thrombodynamics test as initial clot growth rate, average clot growth rate, clot size significantly exceed the reference values and indicate high prothrombogenic potential in patient with AH and MFA. Prescription of dual antiplatelet therapy allows normalization of identified disorders. Presence of risk factors (smoking) aggravates existing hemostasis disorders in patients with AH and MFA.Conclusion. Smoking cessation, optimization of risk factors and complex antihypertensive, hypolipidemic and antithrombotic therapy are the basis of treatment of patients with AH and MFA and can be considered as priority measures to reduce morbidity and mortality in this patient population.

2 August 2026 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
IKI. N. Kupriyanova
I. N. Kupriyanova
ASA. V. Sakhno
A. V. Sakhno
KSK. V. Sudarikova
K. V. Sudarikova
ИКИ. Н. Куприянова
И. Н. Куприянова
АСА. В. Сахно
А. В. Сахно
КСК. В. Сударикова
К. В. Сударикова
Levels of gamma-glutamyl transferase and NT-proBNP in patients with ischemic heart disease and metabolic dysfunction-associated fatty liver disease | Kupriyanova | Experimental and Clinical Gastroenterology Уровень гамма-глутамилтрансферазы и NT-proBNP у пациентов с ишемической болезнью сердца и метаболически-ассоциированная жировая болезнь печени | Куприянова | Экспериментальная и клиническая гастроэнтерология

18 December 2023 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
IKI. N. Kupriyanova
I. N. Kupriyanova
EPE. A. Postnikova
E. A. Postnikova
Tropheryma whipplei and Helicobacter pylori share common transmission routes and epidemiological risk factors. A review of the current literature reflecting the relationship between Whipple’s Disease and Helicobacter pylori is presented.

17 January 2024 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
IKI. N. Kupriyanova
I. N. Kupriyanova
RBR. B. Berdnikov
R. B. Berdnikov
RBR. M. Bozrov
R. M. Bozrov
MSM. A. Stafilova
M. A. Stafilova
The article presents a clinical observation of Whipple’s disease in a 42-year-old patient with a history of stage IIB Hodgkin’s lymphoma, in whom the disease debuted with articular syndrome, lymphadenopathy of the retroperitoneal and mesenteric lymph nodes, deep vein thrombosis of the leg. The diagnosis was confirmed by a morphological study of biopsy specimens of the duodenal mucosa, mesenteric lymph nodes 12 p. of the intestine, electron microscopic detection of accumulations of rod-shaped bacteria in the intestinal mucosa 6 years after the onset of clinical manifestations. Dynamic observation for 5 years was carried out using video gastroduodenoscopy, morphological assessment of changes in xanthoma macrophages proposed by A. Herbay, the percentage of damage by PAS-positive macrophages to the area of the lamina propria of the duodenal mucosa of the intestine. Conducted therapy with ceftriaxone for 14 days followed by taking co-trimaxosole for 4 years 7 months led to a stable remission.